Evidence-informed pharmacology monograph updated 10 November 2026. Educational content, not a substitute for patient-specific assessment, institutional protocols or current product labeling.
Overview and chemical identity
Valsartan is a selective nonpeptide angiotensin II type 1 (AT1) receptor antagonist (ARB), used for hypertension, certain heart-failure regimens and post-myocardial-infarction left ventricular dysfunction. Its correct empirical formula is C24H29N5O3; the previously printed C28H31NO5 and descriptions of a thienopyrrolidine or thiazolidine structure were incorrect. Valsartan is an N-substituted valine derivative containing a biphenyl tetrazole moiety [1,2].
Mechanism of action
Blocking AT1 receptors inhibits angiotensin II–mediated vasoconstriction, aldosterone secretion, renal sodium retention and adverse cardiovascular remodeling. Valsartan does not inhibit ACE and does not increase bradykinin to the same extent as ACE inhibitors, so ACE-inhibitor-type cough is less common. Renal efferent-arteriolar dilation can lower intraglomerular pressure but also lead to an initial rise in creatinine, particularly with volume depletion or kidney disease [1].
Approved indications and dosing distinctions
Valsartan has adult indications including hypertension, heart failure and post-MI management in appropriate patients with LV dysfunction or heart failure. Typical starting doses and titration differ by indication: hypertension may use once-daily regimens, whereas HF and post-MI trials commonly used divided dosing. In HFrEF, valsartan alone is not equivalent to the ARNI sacubitril/valsartan, which has different outcome evidence and dosing. Individual dosing needs clinician review of BP, kidney function and other therapies [1,2].
Pharmacokinetics
Valsartan is given orally, has moderate bioavailability and is predominantly excreted through the biliary/fecal route, with relatively little CYP metabolism. Food can alter exposure without necessarily requiring meal-specific prescribing under current labels. Hepatic disease, volume depletion and interacting medicines can change tolerance; dose adjustments depend on product guidance [1].
Boxed warning: fetal toxicity and key contraindications
Valsartan and other ARBs can injure or kill the developing fetus, particularly through effects on the fetal renin–angiotensin system. Discontinue as soon as pregnancy is recognized and use suitable alternatives when pregnancy is planned. Do not combine valsartan with aliskiren in patients with diabetes under US labeling. Routine ACEi–ARB dual therapy is generally avoided because of hyperkalemia, hypotension and kidney injury [1].
Monitoring and interactions
Monitor BP, serum creatinine/eGFR and potassium after initiation or significant dose increase, generally within 2–4 weeks and sooner with high-risk factors. Hyperkalemia is more likely with potassium supplements, spironolactone or other MRAs. NSAIDs can blunt BP lowering and increase AKI risk in susceptible patients; lithium concentrations may rise. Evaluate significant creatinine increases for hypotension, volume depletion, renovascular disease or other causes rather than assuming every rise represents irreversible renal toxicity [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Valsartan tablets: prescribing information, description, indications and fetal toxicity warning. Updated 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.